JP Morgan Chase
EFTR

JP Morgan Chase’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

JP Morgan Chase’s Portfolio EFTR Stock Details EFTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3
Closed -$32 – 8012
2023
Q4 		$32 Buy
3
+2
+200% +$27 ﹤0.01% 7273
2023
Q3 		$18 Buy
+1
New +$17 ﹤0.01% 7200
2022
Q1 		– Sell
-31
Closed -$6K – 7120
2021
Q4 		$6K Buy
+31
New +$7.2K ﹤0.01% 6403

Other funds holding EFTR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

JP Morgan Chase's EFTR Position: Q1 2024 in Review

JP Morgan Chase sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q1 2024, closing a stake of 3 shares — an estimated $32 sold.

JP Morgan Chase first reported a position in EFTR in Q4 2021 and held it in 3 quarters. The position peaked at $6K in Q4 2021. 17 funds tracked by Wall St. Rank hold EFTR as of Q1 2024.

  • JP Morgan Chase reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • JP Morgan Chase sold 3 eFFECTOR Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $32.
  • JP Morgan Chase first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q4 2021 and held it in 3 quarters.
  • JP Morgan Chase's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $6K in Q4 2021.
  • 17 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q1 2024.

Based on JP Morgan Chase's 13F filing for Q1 2024, filed 10 May 2024.